John Richart is an Oncology physician. OpenAlex indexes 40 publications with 577 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Sponsor: St. Louis University
- Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
Sponsor: St. Louis University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SobiProgram year20244 paymentsResearch$23,900openpaymentsdata.cms.gov ↗
- Merck & Co.Program year20232 paymentsResearch$27,561openpaymentsdata.cms.gov ↗
- Pharmacyclics LLC, An AbbVie CompanyProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”